Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM).
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.
Day One Biopharmaceuticals announced the recently completed submission of the rolling New Drug Application (NDA) to the FDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (LGG). The Company anticipates the FDA will file the rolling NDA by mid-November 2023.
With the release of the 2016 edition of the WHO Classification of Central Nervous System Tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center...
This update covers recommendations for glioblastoma; anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma; and diffuse glioma.
Spectrum Pharmaceuticals announced that the that the company has submitted a New Drug Application (NDA) to the FDA for approval...
The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors).
Italfarmaco S.p.A. announced that the FDA has approved Duvyzat (givinostat), a novel histone deacetylase (HDAC) inhibitor, for the treatment of patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare X-linked progressive and life-limiting neuromuscular condition with symptoms from early childhood.
Adding Zolinza (vorinostat), from Merck, a histone deacetylase inhibitor that activates genes to frontline combination therapy for Acute Myeloid Leukemia...